MABT was founded in 2011 with the simple goal of making a meaningful difference on the lives of patients, families and communities worldwide. We are especially excited about our work on neurodegenerative conditions such as Alzheimer’s, Parkinson’s and ALS.
Mid-Atlantic BioTherapeutics is committed to pushing the boundaries of scientific understanding and therapeutic efficacy to address an unmet need for diseases that are hard to treat. By leveraging the power of biotechnology and artificial intelligence, we believe that we may be able to treat currently incurable diseases.
MABT has multiple novel proprietary technologies that we test for the goal of having a profound impact on hard to treat diseases. We were even the first company ever to qualify for Orphan Drug Designation for Rabies, the world’s most deadly disease with our proprietary technology platform Immunotherapy, IMT504.